January 9, 2018 5:50pm

Traders weren’t “conferencing” in SF and algorithms and ETFs were also not invited!

While the clinical achievement issues of 2016 were not washed away

 

The sector opened up, slid at 11 a.m., stayed down at mid-day and closed to the downside

… As I had stated, “Do we have some catch-up potential today ... YES – for some – MDXG, ONCE, XON, SGMO, QURE, JUNO, HSGX, STML and even KOOL!”

 

Pre-open indications: 4 hits and 3 miss

 

Out and about: Histogenics (HSGX +$0.22) gets $10 M for Neocart agreement: https://www.regmedinvestors.com/articles/10082

The Biostage (BSTG +$0.02) chronicles …

Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s newsletter, “where’s the meat? How long will it take to cook and what will it taste like when it’s done? The old recipe book that’s behind the content and mixing has its pages ripped-out. It’s still all in the timing and one’s appetite … Since we are speaking about the healthcare companies appearing at SF conferences, the privates could end up being the headliners!”

As I had stated, “By the way, where is the buzz from the conferences, maybe today will be better?”

Many traders weren’t “conferencing” in SF and algorithms and ETFs were also not invited!

Invitees have yet to open their wallets to vote for presentations – a lot of talk and no real buying action!

NO "spoil sport" here but the facts, figures, fundamentals are speaking - and many have and had not heard the sirens singing ... !!

 

 

The advance/decline line scenario of 40 SCGT & RT covered companies:   

·         The open was positive with an A/DL of 24/13 and 3 flat ;

·         The mid-day was negative with an A/DL of 14/22 and 4 flat;

·         The close was negative with an A/DL of 18/21 and 2 flat;

 

 

MY working trend lines and indications:

… The greatest volume to the downside:  JUNO, RENE.L, ADVM, IMUC and BLUE

… Upside volume was weighted to:  MDXG, VTGN, CYTX, XON and NWBO

… Biggest $ downside: AXGN (-$1.40), BLUE (-$0.60), BLCM (-$0.55), CLLS (-$0.27) and RGNX (-$0.20)

… Largest $ upside:  MDXG (+$1.63), XON (+$0.96), ONCE (+$0.89), OSIR (+$0.52) and KOOL (+$0.43)

… Flat: VCEL and STML

 

Pre-open indications:

  • Applied Genetic Technologies (AGTC) closed down -$0.15 – hit;
  • bluebird bio (BLUE) closed down -$0.60 – miss;
  • Capricor (CAPR) closed down -$0.02 – hit;
  • Cesca Therapeutics (KOOL) closed up +$0.43 – miss;
  • Osiris Therapeutics (OSIR) closed up +$0.52 – miss;
  • Pluristem (PSIT) closed up +$0.13 – hit;
  • Verastem (VSTM) closed up +$0.02 – hit;

 

Out and about:

Biostage (BSTGD) This management team WIPED OUT 20 M of shareholders holdings and investment!

Opened at $1.97 (previous closed $1.98) then appreciated +$0.02 or -1.01% to close UP at $2.00 in a day’s range of $1.97 to $2.15 with low 7,274 shares traded; the share price had been down as much as -$0.32.  This follows the projected $1.32 post the 1-to-20 reverse split – a $4 M in-flow just followed a $30 M investment loss incurring a $47 M deficit!

NO scientists, a CEO, CFO and 2 accountants don’t make a company who couldn’t pay their rent or communicate their issues to past “fleeced” shareholders …

I am NOT “eating” my negative declaration, my OPINION is still “FRAUD” and “COVER UP of MISDEEDS “by this management team!

 

 

Daily analytics:

U.S. stock benchmarks on Tuesday afternoon finished at fresh records, with the S&P 500 and Nasdaq registering a sixth straight gain for 2018.

·         The Dow tacked on 102.80 points, or 0.4%, to 25,385.80.

·         The S&P 500 index gained 3.58 points, or 0.1%, to 2,751.29.

·         The NASDAQ advanced 6.19 points, or less than 0.1%, at 7,163.58.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Tuesday traded at 10.08, up +5.88% …

  • Monday traded at 9.52, up +3.25% after Friday traded at 9.22, flat at 0.00% after Thursday traded at 9.22, up +0.77% after Wednesday traded at 9.15, down -6.35% and last Tuesday traded at 9.77, down -11.50% …

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Tuesday was down -0.14%

·         Monday was up +0.17%

·         Friday was up +0.21%

·         Thursday was up +0.24%

·         Wednesday was up +0.12%

·         Last Tuesday was up +0.92%

 

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Tuesday was up +1.88%

·         Monday was down -1.33%

·         Friday was down -0.13%

·         Thursday was down -0.82%

·         Wednesday was up +1.41%

·         Last Tuesday was up +2.41%

 

 

The count - decliners versus gainers:

……. look at the differences in decliners:

·         Tuesday’s decliners ranged from -0.28% <JUNO -$0.14> to -5.84% < BLCM -$0.55> in 18 equities;

·         Monday’s decliners ranged from -0.11%% <BLCM -$0.01> to -27.19% <CYTX -$0.13> in 26 equities;

·         Friday’s decliners ranged from -0.28% <BCLI -$0.01> to -20.88% <RGNX -$7.35> in 20 equities;

·         Thursday’s decliners ranged from -0.70% <PSTI -$0.01> to -8.45% <XON -$1.19> in 19 equities;

·         Wednesday’s decliners ranged from -0.62% <MDXG -$0.08> to -5.42% <CUR -$0.11> in 15 equities;

·         Last Tuesday’s decliners ranged from -0.63% <CAPR -$0.01> to -% <BCLI -$0.27> in 7 equities;

Versus

… Look at the percentage’s (%) and spreads …

·         Tuesday’s gainers ranged from +0.68% <VSTM +$0.02> to +12.84% <KOOL +$0.43> in 22 equities;

·         Monday’s gainers ranged from +0.08% <ONCE +$0.04> to +9.16% <BTX +$0.23> in 13 equities;

·         Friday’s gainers ranged from +0.61% <JUNO +$0.29> to +73.75% <CYTX +$0.20> in 18 equities;

·         Thursday’s gainers ranged from +0.45% <QURE +$0.09> to +13.95% <AST +$0.30> in 21 equities;

·         Wednesday’s gainers ranged from +0.32% <KOOL +$0.01> to +17.81% <ADVM +$0.65> in 23 equities

·         Last Tuesday’s gainers ranged from +0.32% <STML +$0.05> to +18.02% <CUR +$0.31> in 31 equities

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.